NanoFlu

BIOLOGICAL2 trials

Sponsors

Novavax

Conditions

InfluenzaInfluenza, Human

Phase 1

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

CompletedNCT03293498

NovavaxInfluenza

Start: 2017-09-18End: 2018-10-29Updated: 2022-12-21

Phase 3

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

CompletedNCT04120194

NovavaxInfluenza, Human

Start: 2019-10-14End: 2020-12-13Updated: 2023-05-06

Related Papers

Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.

2021-09-2349 citations